syn-selective additions to Garner aldehyde: Synthesis of a potent glucosylceramide synthase inhibitor

Tetrahedron Letters

Volumn 43, Issue 47, 2002, Pages 8621-8623

  Husain, Arifa ^a   Ganem, Bruce ^a  

^a Cornell University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR;

ACYLATION; ARTICLE; ASYMMETRIC SYNTHESIS; CATALYSIS; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOSELECTIVITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STEREOCHEMISTRY; STEREOISOMERISM;

EID: 0037131768     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(02)02096-8     Document Type: Article

References (29)

1. Desnick R.J., Ioannou Y.A., Eng C.M. α-Galactosidase A Deficiency: Fabry Disease. Scriver C.R., The Metabolic and Molecular Bases of Inherited Disease. 1995;2741-2784 McGraw-Hill.
2. Beutler E. Curr. Opin. Hematol. 4:1997;19-23.
3. Schiffmann R., Murray G.J., Treco D. Proc. Natl. Acad. Sci. USA. 97:2000;365-370.
4. Radin N. Prog. Clin. Biol. 95:1982;357-383.
5. Ratner L., vander Heyden N., Dedera D. Virology. 181:1991;180-192.
6. Platt F.M., Reinkensmeier G., Dwek R.A., Butters T.D. J. Biol. Chem. 272:1997;19365-19372.
7. Abe A., Inokuchi J., Jimbo M., Shimeno H., Nagamatsu A., Shayman J.A., Shukla G.S., Radin N.S. J. Biochem. (Tokyo). 111:1992;191-196.
8. Carson K.G., Ganem B., Radin N.S., Abe A., Shayman J.A. Tetrahedron Lett. 35:1994;2659-2663.
9. Abe A., Radin N.S., Shayman J.A., Wotring L.L., Zipkin R.E., Sivakumar R., Ruggieri J.M., Carson K.G., Ganem B. J. Lipid Res. 36:1995;611-621.
10. Mitchell S.A., Oates B.D., Razavi H., Polt R. J. Org. Chem. 63:1998;8837-8842.
11. Shayman J.A., Lee L., Abe A., Shu L. Methods Enzymol. 311:2000;373-387.
12. Lee L., Abe A., Shayman J.A. J. Biol. Chem. 274:1999;14662-14669.
13. Abe A., Arend L.J., Lee L., Lingwood C., Brady R.O., Shayman J.A. Kidney Int. 57:2000;446-454.
14. Abe A., Gregory S., Lee L., Killen P.D., Brady R.O., Kulkarni A., Shayman J.A. J. Clin. Invest. 105:2000;1563-1571.
15. Nishida A., Sorimachi H., Iwaida M., Matsumizu M., Kawate T., Nakagawa M. Synthesis. 1998;389-390.
16. . An alternative route to D-threo-1 was recently achieved by stereoselective reduction of the corresponding arylketone: Jimbo M., Yamagishi K., Yamaki T., Nunomura K., Kabayama K., Igarashi Y., Inokuchi J. J. Biochem. 127:2000;485-491.
17. Mengel A., Reiser O. Chem. Rev. 99:1999;1191-1223.
18. Radunz H.-E., Devant R.M., Eiermann V. Liebigs Ann. Chem. 1988;1103-1105.
19. Herold P. Helv. Chim. Acta. 71:1988;354-362.
20. Bayquen A.V., Read R.W. Tetrahedron. 52:1996;13467-13482.
21. . This Grignard reagent was prepared in standard fashion from the corresponding bromide: Mattson R.J., Sloan C.P., Lockhart C.C., Catt J.D., Gao Q., Huang S. J. Org. Chem. 64:1999;8004-8007.
22. 3) δ 7.45-7.26 (m, 5H), 4.83-4.63 (d, J=9.1 Hz, 1H), 4.33-4.07 (m, 1H), 3.81-3.49 (m, 2H), 1.60-1.44 (m, 15H); for 6b: δ 6.95-6.74 (m, 3H), 4.70-4.48 (d, J=8.6 Hz, 1H), 4.21 (s, 4H), 4.14-4.07 (m, 1H), 3.79-3.46 (m, 2H), 1.63-1.40 (m, 15H); for 6c: δ 7.34-7.23 (d, J=8.0 Hz, 2H), 6.91-6.78 (d, J=8.6 Hz, 2H), 4.75-4.59 (d, J=9.1 Hz, 1H), 4.22-4.09 (m, 1H), 3.79 (s, 3H), 3.74-3.51 (m, 2H), 1.57-1.45 (m, 15H).
23. 13C NMR δ 174.1, 143.6, 143.1, 134.5, 119.2, 117.3, 115.3, 76.9, 74.3, 64.6, 57.3, 55.1, 52.5, 46.2, 36.9, 32.2, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 25.9, 23.8, 22.9, 14.4.
24. Grigsby R.J., Dobrowsky R.T. Biochem. Biophys. Res. Commun. 287:2001;1121-1124.
25. Inokuchi J., Jimbo M., Momosaki K., Shimeno H., Nagamatsu A., Radin N.S. Cancer Res. 50:1990;6731-6737.
26. Sietsma H., Veldman R.J., Kok J.W. J. Membrane Biol. 181:2001;153-162.
27. Cheng P.C., Dykstra M.L., Mitchell R.N., Pierce S.K. J. Exp. Med. 190:1999;1549-1560.
28. Mandala S.M., Harris G.H. Methods Enzymol. 311:2000;335-348.
29. Georgopapadakou N.H. Exp. Opin. Invest. Drugs. 9:2000;1787-1796.